Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-04-21

Clinical Trial Update: Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the efficacy and safety of Suzetrigine (SUZ) for pain associated with diabetic peripheral neuropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Suzetrigine (SUZ) (Suzetrigine)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Diabetic Peripheral Neuropathic Pain | Phase 3 | Status: RECRUITING